P-222: Extended follow-up safety and efficacy results of Belantamab mafodotin (Belamaf) 1.92 mg/kg or 2.5 mg/kg combined with POM and DEX for the treatment of relapsed/refractory Multiple Myeloma Conferences uri icon

  •  
  • Overview
  •  
  • Research
  •  
  • Identity
  •  
  • Additional Document Info
  •  
  • View All
  •  

authors

  • Trudel, Suzanne
  • McCurdy, Arleigh
  • Sutherland, Heather
  • Louzada, Martha
  • Venner, Christopher
  • White, Darrell
  • Mian, Hira
  • Kotb, Rami
  • Othman, Ibraheem
  • Camacho, Fernando
  • Fu, Molei
  • Gul, Engin
  • Reece, Donna

publication date

  • October 2021